



Universiteit
Leiden
The Netherlands

Inhibition and dynamics of a β -lactamase

Elings, W.

Citation

Elings, W. (2019, November 19). *Inhibition and dynamics of a β -lactamase*. Retrieved from <https://hdl.handle.net/1887/80412>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/80412>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The following handle holds various files of this Leiden University dissertation:
<http://hdl.handle.net/1887/80412>

Author: Elings, W.

Title: Dynamics of a β -lactamase

Issue Date: 2019-11-19

References

1. Daniel, T. M. The history of tuberculosis. *Respir. Med.* **100**, 1862–1870 (2006).
2. Rubin, S. A. Tuberculosis. Captain of all these men of death. *Radiol. Clin. North Am.* **33**, 619–639 (1995).
3. McAdam, K. P. W. J. Book Review In the shadow of tuberculosis. *N. Engl. J. Med.* **332**, 1106–1109 (1995).
4. World Health Organization. *Global Tuberculosis Report. Tuberculosis* (World Health Organization, 2015). doi:978 92 4 156450 2
5. World Health Organization. *Global tuberculosis report 2016.* (2016).
6. World Health Organization. *Global tuberculosis report 2017.* (2017).
7. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000–2004. *MMWR. Morb. Mortal. Wkly. Rep.* **55**, 301–305 (2006).
8. World Health Organisation. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. *Relev. Epidemiol. Hebd.* **81**, 430–432 (2006).
9. World Health Organisation. WHO | Drug-resistant TB: Totally drug-resistant TB FAQ. *WHO* (2018). Available at: <http://www.who.int/tb/areas-of-work/drug-resistant-tb/totally-drug-resistant-tb-faq/en/>. (Accessed: 28th August 2018)
10. Velayati, A. A. *et al.* Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. *Chest* **136**, 420–425 (2009).
11. Udhwadia, Z. F., Amale, R. A., Ajbani, K. K. & Rodrigues, C. Totally Drug-Resistant Tuberculosis in India. *Clin. Infect. Dis.* **54**, 579–581 (2012).
12. Wallis, R. S. *et al.* Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. *Lancet Infect. Dis.* **16**, e34–e46 (2016).
13. Tiberi, S. *et al.* New drugs and perspectives for new anti-tuberculosis regimens. *Pulmonology* **24**, 86–98 (2018).
14. Voladri, R. K. *et al.* Recombinant expression and characterization of the major beta-lactamase of *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **42**, 1375–1381 (1998).
15. Flores, A. R., Parsons, L. M. & Pavelka, M. S. Genetic analysis of the beta-lactamases of *Mycobacterium tuberculosis* and *Mycobacterium smegmatis* and susceptibility to beta-lactam antibiotics. *Microbiology* **151**, 521–532 (2005).
16. Wang, F., Cassidy, C. & Sacchettini, J. C. Crystal structure and activity studies of the *Mycobacterium tuberculosis* β -lactamase reveal its critical role in resistance to β -lactam antibiotics. *Antimicrob. Agents Chemother.* **50**, 2762–2771 (2006).
17. Ambler, R. P. & Coulson, A. F. W. A standard numbering scheme for the Class A beta-lactamases. *Biochem. J.* **276**, 269–272 (1991).
18. Hugonnet, J.-E. & Blanchard, J. S. Irreversible inhibition of the *Mycobacterium tuberculosis* beta-lactamase by clavulanate. *Biochemistry* **46**, 11998–12004 (2007).

19. Meroueh, S. O., Fisher, J. F., Schlegel, H. B. & Mobashery, S. Ab Initio QM/MM Study of Class A β -Lactamase Acylation: Dual Participation of Glu166 and Lys73 in a Concerted Base Promotion of Ser70. *J. Am. Chem. Soc.* **127**, 15397–15407 (2005).
20. Vandavasi, V. G. *et al.* Exploring the Mechanism of β -Lactam Ring Protonation in the Class A β -lactamase Acylation Mechanism Using Neutron and X-ray Crystallography. *J. Med. Chem.* **59**, 474–479 (2016).
21. Tremblay, L. W., Xu, H. & Blanchard, J. S. Structures of the Michaelis complex (1.2 Å) and the covalent acyl intermediate (2.0 Å) of cefamandole bound in the active sites of the *Mycobacterium tuberculosis* β -lactamase K73A and E166A mutants. *Biochemistry* **49**, 9685–9687 (2010).
22. Chow, C., Xu, H. & Blanchard, J. S. Kinetic characterization of hydrolysis of nitrocefin, cefoxitin, and meropenem by β -lactamase from *Mycobacterium tuberculosis*. *Biochemistry* **52**, 4097–4104 (2013).
23. McDonough, J. A., Hacker, K. E., Flores, A. R., Pavelka, M. S. & Braunstein, M. The twin-arginine translocation pathway of *Mycobacterium smegmatis* is functional and required for the export of mycobacterial beta-lactamases. *J. Bacteriol.* **187**, 7667–7679 (2005).
24. McDonough, J. A. *et al.* Identification of functional Tat signal sequences in *Mycobacterium tuberculosis* proteins. *J. Bacteriol.* **190**, 6428–6438 (2008).
25. Bush, K. Characterization of beta-lactamases. *Antimicrob. Agents Chemother.* **33**, 259–263 (1989).
26. Bush, K., Jacoby, G. A. & Medeiros, A. A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrob. Agents Chemother.* **39**, 1211–1233 (1995).
27. Bush, K. & Jacoby, G. A. Updated functional classification of beta-lactamases. *Antimicrob. Agents Chemother.* **54**, 969–976 (2010).
28. Elings, W. *et al.* Phosphate promotes the recovery of *Mycobacterium tuberculosis* β -lactamase from clavulanic acid inhibition. *Biochemistry* **56**, 6257–6267 (2017).
29. Kurz, S. G. *et al.* Can inhibitor-resistant substitutions in the *Mycobacterium tuberculosis* β -Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β -lactam- β -lactamase inhibitor combinations. *Antimicrob. Agents Chemother.* **57**, 6085–6096 (2013).
30. Feiler, C. *et al.* Directed evolution of *Mycobacterium tuberculosis* β -lactamase reveals gatekeeper residue that regulates antibiotic resistance and catalytic efficiency. *PLoS One* **8**, e73123 (2013).
31. Doucet, N., De Wals, P.-Y. & Pelletier, J. N. Site-saturation mutagenesis of Tyr-105 reveals its importance in substrate stabilization and discrimination in TEM-1 beta-lactamase. *J. Biol. Chem.* **279**, 46295–46303 (2004).
32. Jelsch, C., Mourey, L., Masson, J.-M. & Samama, J.-P. Crystal structure of *Escherichia coli* TEM1 β -lactamase at 1.8 Å resolution. *Proteins Struct. Funct. Genet.* **16**, 364–383 (1993).
33. Kuzin, A. P. *et al.* Structure of the SHV-1 β -Lactamase. *Biochemistry* **38**, 5720–5727 (1999).
34. Tremblay, L. W., Fan, F. & Blanchard, J. S. Biochemical and Structural Characterization of *Mycobacterium tuberculosis* β -Lactamase with the

- Carbapenems Ertapenem and Doripenem. *Biochemistry* **49**, 3766–3773 (2010).
35. Robin, F. *et al.* TEM-109 (CMT-5), a natural complex mutant of TEM-1 beta-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5). *Antimicrob. Agents Chemother.* **49**, 4443–4447 (2005).
36. Poirel, L. *et al.* Emergence in *Klebsiella pneumoniae* of a chromosome-encoded SHV beta-lactamase that compromises the efficacy of imipenem. *Antimicrob. Agents Chemother.* **47**, 755–758 (2003).
37. Ourghanlian, C., Soroka, D. & Arthur, M. Inhibition by avibactam and clavulanate of the β -lactamases KPC-2 and CTX-M-15 harboring the substitution N132G in the conserved motif SDN. *AAC Accept. Manuscr. Posted Online Antimicrob. Agents Chemother* (2017). doi:10.1128/AAC.02510-16
38. Drawz, S. M. & Bonomo, R. A. Three decades of β -lactamase inhibitors. *Clin. Microbiol. Rev.* **23**, 160–201 (2010).
39. van den Akker, F. & Bonomo, R. A. Exploring additional dimensions of complexity in inhibitor design for serine β -lactamases: mechanistic and intra- and intermolecular chemistry approaches. *Front. Microbiol.* **9**, 622 (2018).
40. Bush, K. & Bradford, P. A. Interplay between β -lactamases and new β -lactamase inhibitors. *Nat. Rev. Microbiol.* **17**, 295–306 (2019).
41. Xu, H., Hazra, S. & Blanchard, J. S. NXL104 irreversibly inhibits the β -lactamase from *Mycobacterium tuberculosis*. *Biochemistry* **51**, 4551–4557 (2012).
42. Kurz, S. G. *et al.* Inhibiting the beta-lactamase of *Mycobacterium tuberculosis* (Mtb) with novel boronic acid transition-state inhibitors (BATSI)s. *ACS Infect. Dis.* **1**, 234–242 (2016).
43. Hazra, S., Xu, H. & Blanchard, J. S. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β -lactamase from *Mycobacterium tuberculosis*. *Biochemistry* **53**, 3671–3678 (2014).
44. Hazra, S. *et al.* Kinetic and structural characterization of the interaction of 6-methylidene penem 2 with the beta-lactamase from *Mycobacterium tuberculosis*. *Biochemistry* **54**, 5657–5664 (2015).
45. Chambers, H. F. *et al.* Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? *Antimicrob. Agents Chemother.* **39**, 2620–2624 (1995).
46. Kurz, S. G. & Bonomo, R. A. Reappraising the use of β -lactams to treat tuberculosis. *Expert Rev. Anti. Infect. Ther.* **10**, 999–1006 (2012).
47. Hugonnet, J.-E., Tremblay, L. W., Boshoff, H. I., Barry, C. E. & Blanchard, J. S. Meropenem-clavulanate is effective against extensively drug-resistant *Mycobacterium tuberculosis*. *Science* **323**, 1215–1218 (2009).
48. Payen, M. C. *et al.* Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. *Int. J. Tuberc. Lung Dis.* **16**, 558–560 (2012).
49. Gonzalo, X. & Drobniewski, F. Is there a place for β -lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. *J. Antimicrob. Chemother.* **68**, 366–369 (2013).
50. Forsman, L. D. *et al.* Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **59**, 3630–3632 (2015).

51. Jaganath, D., Lamichhane, G. & Shah, M. Carbapenems against *Mycobacterium tuberculosis*: a review of the evidence. *Int. J. Tuberc. Lung Dis.* **20**, 1436–1447 (2016).
52. Payen, M. C. *et al.* Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases. *Int. J. Tuberc. Lung Dis.* **22**, 34–39 (2018).
53. Tiberi, S. *et al.* Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. *Eur. Respir. J.* **47**, 1235–1243 (2016).
54. Tiberi, S. *et al.* Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. *Eur. Respir. J.* 13993003.00214-2016- (2016). doi:10.1183/13993003.00214-2016
55. Chambers, H. F., Kocagöz, T., Sipit, T., Turner, J. & Hopewell, P. C. Activity of amoxicillin/clavulanate in patients with tuberculosis. *Clin. Infect. Dis.* **26**, 874–877 (1998).
56. Rullas, J. *et al.* Combinations of β -lactam antibiotics currently in clinical trials are efficacious in a DHP-I deficient mice model of TB infection. *Antimicrob. Agents Chemother.* **59**, 4997–4999 (2015).
57. Li, F. *et al.* In Vitro Activity of β -Lactams in Combination with β -Lactamase Inhibitors against *Mycobacterium tuberculosis* Clinical Isolates. *Biomed Res. Int.* **2018**, 3579832 (2018).
58. De Lorenzo, S. *et al.* Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. *Eur. Respir. J.* **41**, 1386–1392 (2013).
59. England, K. *et al.* Meropenem-clavulanic acid shows activity against *Mycobacterium tuberculosis* *in vivo*. *Antimicrob. Agents Chemother.* **56**, 3384–3387 (2012).
60. Dhar, N. *et al.* Rapid cytolysis of *Mycobacterium tuberculosis* by faropenem, an orally bioavailable β -lactam antibiotic. *Antimicrob. Agents Chemother.* **59**, 1308–1319 (2015).
61. Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. V. Molecular mechanisms of antibiotic resistance. *Nat. Rev. Microbiol.* **13**, 42–51 (2015).
62. Delcour, A. H. Outer membrane permeability and antibiotic resistance. *Biochim. Biophys. Acta - Proteins Proteomics* **1794**, 808–816 (2009).
63. Blondiaux, N. *et al.* Reversion of antibiotic resistance in *Mycobacterium tuberculosis* by spiroisoxazoline SMART-420. *Science* **355**, 1206–1211 (2017).
64. Hall, B. G. & Barlow, M. Evolution of the serine beta-lactamases: past, present and future. *Drug Resist. Updat.* **7**, 111–123 (2004).
65. Sulton, D. *et al.* Clavulanic Acid Inactivation of SHV-1 and the Inhibitor-resistant S130G SHV-1 β -Lactamase. *J. Biol. Chem.* **280**, 35528–35536 (2005).
66. Thomson, J. M., Distler, A. M., Prati, F. & Bonomo, R. A. Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance. *J. Biol. Chem.* **281**, 26734–26744 (2006).
67. Helfand, M. S. *et al.* Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130. *J.*

- Biol. Chem.* **278**, 52724–52729 (2003).
68. Mendonça, N. *et al.* The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. *Antimicrob. Agents Chemother.* **52**, 1806–1811 (2008).
 69. Papp-Wallace, K. M., Winkler, M. L., Taracila, M. A. & Bonomo, R. A. Variants of β -lactamase KPC-2 that are resistant to inhibition by avibactam. *Antimicrob. Agents Chemother.* **59**, 3710–7 (2015).
 70. Bermudes, H. *et al.* Molecular Characterization of TEM-59 (IRT-17), a Novel Inhibitor-Resistant TEM-Derived beta -Lactamase in a Clinical Isolate of *Klebsiella oxytoca*. *Antimicrob. Agents Chemother.* **43**, 1657–1661 (1999).
 71. Drawz, S. M. *et al.* The Role of a Second-Shell Residue in Modifying Substrate and Inhibitor Interactions in the SHV β -Lactamase: A Study of Ambler Position Asn276. *Biochemistry* **48**, 4557–4566 (2009).
 72. Prinarakis, E. E., Miriagou, V., Tzelepi, E., Gazouli, M. & Tzouveleki, L. S. Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant. *Antimicrob. Agents Chemother.* **41**, 838–840 (1997).
 73. Egesborg, P., Carlettini, H., Volpato, J. P. & Doucet, N. Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β -lactamase from *Mycobacterium tuberculosis*. *Protein Sci.* **24**, 534–544 (2015).
 74. Soroka, D. *et al.* Hydrolysis of clavulanate by *Mycobacterium tuberculosis* β -lactamase BlaC harboring a canonical SDN motif. *Antimicrob. Agents Chemother.* **59**, 5714–5720 (2015).
 75. Soroka, D. *et al.* Inhibition of β -lactamases of mycobacteria by avibactam and clavulanate. *J. Antimicrob. Chemother.* **72**, 1081–1088 (2017).
 76. Yon, J. M., Perahia, D. & Ghélis, C. Conformational dynamics and enzyme activity. *Biochimie* **80**, 33–42 (1998).
 77. Wand, A. J. Dynamic activation of protein function: A view emerging from NMR spectroscopy. *Nat. Struct. Biol.* **8**, 926–931 (2001).
 78. Kay, L. E. NMR studies of protein structure and dynamics. *J. Magn. Reson.* **173**, 193–207 (2005).
 79. Mittermaier, A. K. & Kay, L. E. Observing biological dynamics at atomic resolution using NMR. *Trends Biochem. Sci.* **34**, 601–611 (2009).
 80. Bellissent-Funel, M.-C. *et al.* Water Determines the Structure and Dynamics of Proteins. *Chem. Rev.* **116**, 7673–7697 (2016).
 81. Kovermann, M., Rogne, P. & Wolf-Watz, M. Protein dynamics and function from solution state NMR spectroscopy. *Quarterly reviews of biophysics* **49**, e6 (2016).
 82. Narayanan, C., Bafna, K., Roux, L. D., Agarwal, P. K. & Doucet, N. Applications of NMR and computational methodologies to study protein dynamics. *Arch. Biochem. Biophys.* **628**, 71–80 (2017).
 83. Petrović, D., Risso, V. A., Kamerlin, S. C. L. & Sanchez-Ruiz, J. M. Conformational dynamics and enzyme evolution. *J. R. Soc. Interface* **15**, (2018).
 84. Abragam, A. The principles of nuclear magnetism. *Nucl. Phys.* **28**, 692–693 (1961).
 85. Lipari, G. & Szabo, A. Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity. *J. Am. Chem. Soc.* **104**, 4546–4559 (1982).
 86. Lipari, G. & Szabo, A. Model-free approach to the interpretation of nuclear

- magnetic resonance relaxation in macromolecules. 2. Analysis of experimental results. *J. Am. Chem. Soc.* **104**, 4559–4570 (1982).
87. Korzhnev, D. M., Billeter, M., Arseniev, A. S. & Orekhov, V. Y. NMR studies of Brownian tumbling and internal motions in proteins. *Prog. Nucl. Magn. Reson. Spectrosc.* **38**, 197–266 (2001).
 88. d’Auvergne, E. J. Protein dynamics: a study of the model-free analysis of NMR relaxation data. (2006).
 89. Cavanagh, J., Skelton, N. J., Fairbrother, W. J., Rance, M. & Palmer, A. G. I. *Protein NMR spectroscopy : principles and practice*. (Academic Press, 2007).
 90. Keeler, J. *Understanding NMR spectroscopy*. (John Wiley and Sons, 2010).
 91. Walker, O., Varadan, R. & Fushman, D. Efficient and accurate determination of the overall rotational diffusion tensor of a molecule from ¹⁵N relaxation data using computer program ROTDIF. *J. Magn. Reson.* **168**, 336–345 (2004).
 92. Carr, H. Y. & Purcell, E. M. Effects of Diffusion on Free Precession in Nuclear Magnetic Resonance Experiments. *Phys. Rev.* **94**, 630–638 (1954).
 93. Meiboom, S. & Gill, D. Modified Spin-Echo Method for Measuring Nuclear Relaxation Times. *Rev. Sci. Instrum.* **29**, 688–691 (1958).
 94. Ishima, R. CPMG Relaxation Dispersion. in 29–49 (Humana Press, Totowa, NJ, 2014). doi:10.1007/978-1-62703-658-0_2
 95. Bloch, F. Nuclear Induction. *Phys. Rev.* **70**, 460–474 (1946).
 96. McConnell, H. M. Reaction Rates by Nuclear Magnetic Resonance. *J. Chem. Phys.* **28**, 430–431 (1958).
 97. Hansen, D. F., Vallurupalli, P., Lundström, P., Neudecker, P. & Kay, L. E. Probing chemical shifts of invisible states of proteins with relaxation dispersion NMR spectroscopy: How well can we do? *J. Am. Chem. Soc.* **130**, 2667–2675 (2008).
 98. Palmer, A. G., Kroenke, C. D. & Patrick Loria, J. Nuclear Magnetic Resonance Methods for Quantifying Microsecond-to-Millisecond Motions in Biological Macromolecules. *Methods Enzymol.* **339**, 204–238 (2001).
 99. Ban, D. *et al.* Exceeding the limit of dynamics studies on biomolecules using high spin-lock field strengths with a cryogenically cooled probehead. *J. Magn. Reson.* **221**, 1–4 (2012).
 100. Vallurupalli, P., Bouvignies, G. & Kay, L. E. Studying ‘invisible’ excited protein states in slow exchange with a major state conformation. *J. Am. Chem. Soc.* **134**, 8148–8161 (2012).
 101. Savard, P.-Y. & Gagné, S. M. Backbone dynamics of TEM-1 determined by NMR: Evidence for a highly ordered protein. *Biochemistry* **45**, 11414–11424 (2006).
 102. Fiset, O., Morin, S., Savard, P.-Y., Lagüe, P. & Gagné, S. M. TEM-1 backbone dynamics-insights from combined molecular dynamics and nuclear magnetic resonance. *Biophys. J.* **98**, 637–645 (2010).
 103. Doucet, N., Savard, P.-Y., Pelletier, J. N. & Gagné, S. M. NMR investigation of Tyr105 mutants in TEM-1 beta-lactamase: dynamics are correlated with function. *J. Biol. Chem.* **282**, 21448–21459 (2007).
 104. Morin, S. & Gagné, S. M. NMR Dynamics of PSE-4 β-Lactamase: An Interplay of ps-ns Order and μs-ms Motions in the Active Site. *Biophys. J.* **96**, 4681–4691 (2009).
 105. Roccatano, D. *et al.* Dynamical Aspects of TEM-1 β-Lactamase Probed by Molecular Dynamics. *J. Comput. Aided. Mol. Des.* **19**, 329–340 (2005).

106. Fisette, O., Gagné, S. & Lagüe, P. Molecular Dynamics of Class A β -lactamases—Effects of Substrate Binding. *Biophys. J.* **103**, 1790–1801 (2012).
107. Clouthier, C. M. *et al.* Chimeric β -Lactamases: Global Conservation of Parental Function and Fast Time-Scale Dynamics with Increased Slow Motions. *PLoS One* **7**, e52283 (2012).
108. Risso, V. A., Gavira, J. A., Mejia-Carmona, D. F., Gaucher, E. A. & Sanchez-Ruiz, J. M. Hyperstability and Substrate Promiscuity in Laboratory Resurrections of Precambrian β -Lactamases. *J. Am. Chem. Soc.* **135**, 2899–2902 (2013).
109. Zou, T., Risso, V. A., Gavira, J. A., Sanchez-Ruiz, J. M. & Ozkan, S. B. Evolution of Conformational Dynamics Determines the Conversion of a Promiscuous Generalist into a Specialist Enzyme. *Mol. Biol. Evol.* **32**, 132–143 (2015).
110. Risso, V. A. *et al.* De novo active sites for resurrected Precambrian enzymes. *Nat. Commun.* **8**, 16113 (2017).
111. Gobeil, S. M. C. *et al.* Maintenance of Native-like Protein Dynamics May Not Be Required for Engineering Functional Proteins. *Chem. Biol.* **21**, 1330–1340 (2014).
112. Frederick, T. E. & Peng, J. W. A gratuitous β -Lactamase inducer uncovers hidden active site dynamics of the *Staphylococcus aureus* BlaR1 sensor domain. *PLoS One* **13**, e0197241 (2018).
113. Knox, R., Lento, C. & Wilson, D. J. Mapping Conformational Dynamics to Individual Steps in the TEM-1 β -Lactamase Catalytic Mechanism. *J. Mol. Biol.* (2018). doi:10.1016/J.JMB.2018.06.045
114. Storz, J. F. Compensatory mutations and epistasis for protein function. *Current Opinion in Structural Biology* **50**, 18–25 (2018).
115. de Visser, J. A. G. M. & Krug, J. Empirical fitness landscapes and the predictability of evolution. *Nat. Rev. Genet.* **15**, 480–490 (2014).
116. Fowler, D. M. & Fields, S. Deep mutational scanning: a new style of protein science. *Nat. Methods* **11**, 801–807 (2014).
117. Kitzman, J. O., Starita, L. M., Lo, R. S., Fields, S. & Shendure, J. Massively parallel single-amino-acid mutagenesis. *Nat. Methods* **12**, 203–206, 4 p following 206 (2015).
118. Gupta, K. & Varadarajan, R. Insights into protein structure, stability and function from saturation mutagenesis. *Curr. Opin. Struct. Biol.* **50**, 117–125 (2018).
119. Firnberg, E. & Ostermeier, M. PFunkel: Efficient, Expansive, User-Defined Mutagenesis. *PLoS One* **7**, e52031 (2012).
120. Firnberg, E., Labonte, J. W., Gray, J. J. & Ostermeier, M. A Comprehensive, High-Resolution Map of a Gene's Fitness Landscape. *Mol. Biol. Evol.* **31**, 1581–1592 (2014).
121. Stiffler, M. A., Hekstra, D. R. & Ranganathan, R. Evolvability as a function of purifying selection in TEM-1 β -lactamase. *Cell* **160**, 882–892 (2015).
122. Steinberg, B. & Ostermeier, M. Shifting Fitness and Epistatic Landscapes Reflect Trade-offs along an Evolutionary Pathway. *J. Mol. Biol.* **428**, 2730–2743 (2016).
123. Wilson, D. S. & Keefe, A. D. Random mutagenesis by PCR. *Curr. Protoc. Mol. Biol.* **Chapter 8**, Unit8.3 (2001).
124. Cirino, P. C., Mayer, K. M. & Umeno, D. Generating Mutant Libraries Using Error-Prone PCR. in *Directed Evolution Library Creation* 3–10 (Humana Press, 2003). doi:10.1385/1-59259-395-X:3

125. Firnberg, E. & Ostermeier, M. The genetic code constrains yet facilitates Darwinian evolution. *Nucleic Acids Res.* **41**, 7420–8 (2013).
126. Bershtein, S., Segal, M., Bekerman, R., Tokuriki, N. & Tawfik, D. S. Robustness–epistasis link shapes the fitness landscape of a randomly drifting protein. *Nature* **444**, 929–932 (2006).
127. Salverda, M. L. M. *et al.* Initial mutations direct alternative pathways of protein evolution. *PLoS Genet.* **7**, e1001321 (2011).
128. Jacquier, H. *et al.* Capturing the mutational landscape of the beta-lactamase TEM-1. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 13067–13072 (2013).
129. Canale, A. S., Cote-Hammarlof, P. A., Flynn, J. M. & Bolon, D. N. Evolutionary mechanisms studied through protein fitness landscapes. *Curr. Opin. Struct. Biol.* **48**, 141–148 (2018).
130. Tremblay, L. W., Hugonnet, J.-E. & Blanchard, J. S. Structure of the covalent adduct formed between *Mycobacterium tuberculosis* beta-lactamase and clavulanate. *Biochemistry* **47**, 5312–5316 (2008).
131. Mire, J. A. BlaC E166A faropenem acyl-intermediate complex. *Protein Data Bank* DOI: 10.2210/pdb4ebl/pdb (2013). doi:10.2210/pdb4ebl/pdb
132. Tremblay, L. W. & Blanchard, J. S. Crystal structure of BlaC-E166A covalently bound with cefuroxime. *Protein Data Bank* DOI: 10.2210/pdb3nbl/pdb (2011). doi:10.2210/pdb3nbl/pdb
133. Xie, H. *et al.* Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-specific fluorogenic probe. *Nat. Chem.* **4**, 802–809 (2012).
134. Sutcliffe, I. C. & Harrington, D. J. Lipoproteins of *Mycobacterium tuberculosis*: An abundant and functionally diverse class of cell envelope components. *FEMS Microbiol. Rev.* **28**, 645–659 (2004).
135. Gu, S. *et al.* Comprehensive proteomic profiling of the membrane constituents of a *Mycobacterium tuberculosis* strain. *Mol. Cell. Proteomics* **2**, 1284–1296 (2003).
136. Tassoni, R. Structural characterization of bacterial proteins involved in antibiotic resistance and peptidoglycan biosynthesis. (Leiden, 2018).
137. Chen, Y., Bonnet, R. & Shoichet, B. K. The acylation mechanism of CTX-M β -lactamase at 0.88 Å resolution. *J. Am. Chem. Soc.* **129**, 5378–5380 (2007).
138. Pernet, L., Petrella, S. & Sougakoff, W. Crystal structure of the class A beta-lactamase L2 from *Stenotrophomonas maltophilia* at 1.51 angstrom. *Protein Data Bank* DOI: 10.2210/pdb1o7e/pdb (2004). doi:10.2210/pdb1o7e/pdb
139. Marciano, D. C. *et al.* Genetic and structural characterization of an L201P global suppressor substitution in TEM-1 β -lactamase. *J. Mol. Biol.* **384**, 151–164 (2008).
140. Levitte, S. *et al.* Mycobacterial acid tolerance enables phagolysosomal survival and establishment of tuberculous infection in vivo. *Cell Host Microbe* **20**, 250–258 (2016).
141. Nelson, D. L. & Cox, M. M. Lehninger Principles of biochemistry. in 497 (2005).
142. Artimo, P. *et al.* ExpASY: SIB bioinformatics resource portal. *Nucleic Acids Res.* **40**, W597–W603 (2012).
143. Vranken, W. F. *et al.* The CCPN data model for NMR spectroscopy: Development of a software pipeline. *Proteins: Struct., Funct., Bioinf.* **59**, 687–696 (2005).
144. Greives, N. & Zhou, H.-X. Both protein dynamics and ligand concentration can shift the binding mechanism between conformational selection and induced fit. *Proc.*

- Natl. Acad. Sci. U. S. A.* **111**, 10197–10202 (2014).
145. Vogt, A. D. & Di Cera, E. Conformational selection or induced fit? A critical appraisal of the kinetic mechanism. *Biochemistry* **51**, 5894–5902 (2012).
 146. Du, X. *et al.* Insights into Protein-Ligand Interactions: Mechanisms, Models, and Methods. *Int. J. Mol. Sci.* **17**, (2016).
 147. Bhabha, G. *et al.* A Dynamic Knockout Reveals That Conformational Fluctuations Influence the Chemical Step of Enzyme Catalysis. *Science* **332**, 234–238 (2011).
 148. Kohen, A. Role of Dynamics in Enzyme Catalysis: Substantial versus Semantic Controversies. *Acc. Chem. Res.* **48**, 466–473 (2015).
 149. Olmos, J. L. *et al.* Enzyme intermediates captured “on the fly” by mix-and-inject serial crystallography. *BMC Biol.* **16**, 59 (2018).
 150. Pervushin, K., Riek, R., Wider, G. & Wüthrich, K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. *Proc. Natl. Acad. Sci. U. S. A.* **94**, 12366–12371 (1997).
 151. Renner, C., Schleicher, M., Moroder, L. & Holak, T. A. Practical aspects of the 2D $^{15}\text{N}\{-^1\text{H}\}$ -NOE experiment. *J. Biomol. NMR* **23**, 23–33 (2002).
 152. Gong, Q. & Ishima, R. $^{15}\text{N}\{-^1\text{H}\}$ NOE experiment at high magnetic field strengths. *J. Biomol. NMR* **37**, 147–157 (2007).
 153. Ferrage, F., Piserchio, A., Cowburn, D. & Ghose, R. On the measurement of $^{15}\text{N}\{-^1\text{H}\}$ nuclear Overhauser effects. *J. Magn. Reson.* **192**, 302–13 (2008).
 154. Ferrage, F., Reichel, A., Battacharya, S., Cowburn, D. & Ghose, R. On the measurement of $^{15}\text{N}\{-^1\text{H}\}$ nuclear Overhauser effects. 2. Effects of the saturation scheme and water signal suppression. *J. Magn. Reson.* **207**, 294–303 (2010).
 155. Ferrage, F., Cowburn, D. & Ghose, R. Accurate Sampling of High-Frequency Motions in Proteins by Steady-State $^{15}\text{N}\{-^1\text{H}\}$ Nuclear Overhauser Effect Measurements in the Presence of Cross-Correlated Relaxation. *J. Am. Chem. Soc.* **131**, 6048–6049 (2009).
 156. García de la Torre, J., Huertas, M. . & Carrasco, B. HYDRONMR: Prediction of NMR Relaxation of Globular Proteins from Atomic-Level Structures and Hydrodynamic Calculations. *J. Magn. Reson.* **147**, 138–146 (2000).
 157. Stivers, J. T., Abeygunawardana, C., Mildvan, A. S. & Whitman, C. P. ^{15}N NMR Relaxation Studies of Free and Inhibitor-Bound 4-Oxalocrotonate Tautomerase: Backbone Dynamics and Entropy Changes of an Enzyme upon Inhibitor Binding. *Biochemistry* **35**, 16036–16047 (1996).
 158. Tremblay, L. W., Hugonnet, J. E. & Blanchard, J. S. Crystal structure of the covalent adduct formed between TB B-lactamase and clavulanate. *Protein Data Bank* DOI: 10.2210/pdb3cg5/pdb (2008). doi:10.2210/pdb3cg5/pdb
 159. Sagar, A., Haleem, N., Bashir, Y. M. & Ashish. Search for non-lactam inhibitors of mtb β -lactamase led to its open shape in apo state: new concept for antibiotic design. *Sci. Rep.* **7**, 6204 (2017).
 160. Tassoni, R., Blok, A., Pannu, N. S. & Ubbink, M. New Conformations of Acylation Adducts of Inhibitors of β -Lactamase from *Mycobacterium tuberculosis*. *Biochemistry* **58**, 997–1009 (2019).
 161. Bruker Corporation. Dynamics Center Manual. **003**, 110 (2018).
 162. Woessner, D. E. Nuclear Spin Relaxation in Ellipsoids Undergoing Rotational

- Brownian Motion. *J. Chem. Phys.* **37**, 647–654 (1962).
163. Vallurupalli, P., Hansen, D. F., Stollar, E., Meirovitch, E. & Kay, L. E. Measurement of bond vector orientations in invisible excited states of proteins. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 18473–18477 (2007).
 164. Delaglio, F. *et al.* NMRPipe: A multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR* **6**, 277–293 (1995).
 165. Hansen, D. F. *et al.* An exchange-free measure of ¹⁵N transverse relaxation: An NMR spectroscopy application to the study of a folding intermediate with pervasive chemical exchange. *J. Am. Chem. Soc.* **129**, 11468–11479 (2007).
 166. Galleni, M. *et al.* Use of the chromosomal class A beta-lactamase of *Mycobacterium fortuitum* D316 to study potentially poor substrates and inhibitory beta-lactam compounds. *Antimicrob. Agents Chemother.* **38**, 1608–1614 (1994).
 167. Sauvage, E. *et al.* Crystal structure of the *Mycobacterium fortuitum* class A beta-lactamase: structural basis for broad substrate specificity. *Antimicrob. Agents Chemother.* **50**, 2516–2521 (2006).
 168. Lenfant, F., Labia, R. & Masson, J. M. Replacement of lysine 234 affects transition state stabilization in the active site of beta-lactamase TEM1. *J. Biol. Chem.* **169**, 17187–17194 (1991).
 169. Winkler, M. L. *et al.* Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β -lactamase. *J. Med. Chem.* **56**, 1084–1097 (2013).
 170. Inoue, H., Nojima, H. & Okayama, H. High efficiency transformation of *Escherichia coli* with plasmids. *Gene* **96**, 23–28 (1990).
 171. Winkler, M. L., Papp-Wallace, K. M., Taracila, M. A. & Bonomo, R. A. Avibactam and inhibitor-resistant SHV β -lactamases. *Antimicrob. Agents Chemother.* **59**, 3700–3709 (2015).
 172. Krishnan, N. P., Nguyen, N. Q., Papp-Wallace, K. M., Bonomo, R. A. & van den Akker, F. Inhibition of *Klebsiella* β -Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study. *PLoS One* **10**, e0136813 (2015).
 173. Coulondre, C. & Miller, J. H. Genetic studies of the lac repressor: IV. Mutagenic specificity in the lacI gene of *Escherichia coli*. *J. Mol. Biol.* **117**, 577–606 (1977).
 174. Hart, K. M., Ho, C. M. W., Dutta, S., Gross, M. L. & Bowman, G. R. Modelling proteins' hidden conformations to predict antibiotic resistance. *Nat. Commun.* **7**, 12965 (2016).
 175. Bershtein, S., Serohijos, A. W. & Shakhnovich, E. I. Bridging the physical scales in evolutionary biology: from protein sequence space to fitness of organisms and populations. *Curr. Opin. Struct. Biol.* **42**, 31–40 (2017).
 176. Bastolla, U., Dehouck, Y. & Echave, J. What evolution tells us about protein physics, and protein physics tells us about evolution. *Curr. Opin. Struct. Biol.* **42**, 59–66 (2017).
 177. Figliuzzi, M., Jacquier, H., Schug, A., Tenailon, O. & Weigt, M. Coevolutionary Landscape Inference and the Context-Dependence of Mutations in Beta-Lactamase TEM-1. *Mol. Biol. Evol.* **33**, 268–280 (2016).
 178. Fritz, R., Alzate-Morales, J. H., Spencer, J., Mulholland, A. J. & van der Kamp, M. W. Multiscale simulations of clavulanate inhibition identify the reactive complex in class A β -lactamases and predict efficiency of inhibition. *Biochemistry*

- acs.biochem.8b00480 (2018). doi:10.1021/acs.biochem.8b00480
179. Cortina, G. A. & Kasson, P. M. Predicting allosteric and microbial drug resistance with molecular simulations. *Curr. Opin. Struct. Biol.* **52**, 80–86 (2018).
180. Latallo, M. J., Cortina, G. A., Faham, S., Nakamoto, R. K. & Kasson, P. M. Predicting allosteric mutants that increase activity of a major antibiotic resistance enzyme. *Chem. Sci.* **8**, 6484–6492 (2017).
181. Pande, V. S., Beauchamp, K. & Bowman, G. R. Everything you wanted to know about Markov State Models but were afraid to ask. *Methods* **52**, 99–105 (2010).
182. Zimmerman, M. I. *et al.* Prediction of New Stabilizing Mutations Based on Mechanistic Insights from Markov State Models. *ACS Cent. Sci.* **3**, 1311–1321 (2017).
183. Siddiq, M. A., Hochberg, G. K. & Thornton, J. W. Evolution of protein specificity: insights from ancestral protein reconstruction. *Curr. Opin. Struct. Biol.* **47**, 113–122 (2017).
184. Bush, K. Past and Present Perspectives on β -Lactamases. *Antimicrob. Agents Chemother.* **62**, e01076-18 (2018).
185. Tehrani, K. H. M. E. & Martin, N. I. β -lactam/ β -lactamase inhibitor combinations: an update. *Medchemcomm* **9**, 1439–1456 (2018).
186. Avci, F. G., Altinisik, F. E., Ulu, D. V., Olmez, E. O. & Akbulut, B. S. An evolutionarily conserved allosteric site modulates beta-lactamase activity. *J. Enzyme Inhib. Med. Chem.* (2016). doi:10.1080/14756366.2016.1201813
187. Avci, F. G. *et al.* Targeting a hidden site on class A beta-lactamases. *J. Mol. Graph. Model.* **84**, 125–133 (2018).
188. Deshpande, D. *et al.* Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis. *Sci. Adv.* **3**, e1701102 (2017).
189. Lefebvre, A.-L. *et al.* Bactericidal and intracellular activity of β -lactams against *Mycobacterium abscessus*. *J. Antimicrob. Chemother.* dkw022- (2016). doi:10.1093/jac/dkw022
190. Kaushik, A. *et al.* Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant *Mycobacterium abscessus*. *Future Microbiol.* fmb-2016-0234 (2017). doi:10.2217/fmb-2016-0234
191. Kaushik, A. *et al.* In vitro activity of the new β -lactamase inhibitors relebactam and vaborbactam in combination with β -lactams against *Mycobacterium abscessus* complex clinical isolates. *Antimicrob. Agents Chemother.* AAC.02623-18 (2019). doi:10.1128/AAC.02623-18